Medical Cannabis Cuts Opioid Use in Chronic Pain Patients

A small but carefully constructed observational study from the University of Pennsylvania found that chronic pain patients given access to medical cannabis — with cost removed as an obstacle — significantly reduced their opioid use over five months, with nearly a quarter discontinuing opioids entirely.

The study, published on April 17, 2026, in the Cureus Journal of Medical Science, followed 29 adults at the Hospital of the University of Pennsylvania who had been living with chronic pain and managing it with long-term opioid therapy — with a median opioid use duration of 11 years. All had previously attempted to taper without success.

What the Researchers Found

The reductions were notable for a small study. Mean daily opioid use fell from 46.8 morphine milligram equivalents (MMEs) at baseline to 16.2 MMEs at one month — a 65% reduction — and that reduction held through the full five-month follow-up. Seven of the 29 patients (24%) discontinued opioids altogether during the study period, five of them by the second month.

Pain scores improved alongside opioid reductions. Using the standard Numeric Pain Rating Scale, the mean score dropped from 7.03 to 5.07 at one month — a two-point decline that was statistically significant (p < 0.0001) and sustained through the end of the study. Physical functioning scores, measured with the SF-36 Health Survey at baseline, two months, and five months, improved from 15.3 at baseline to 21.4 at two months and 21.6 at five months (p < 0.03 for both comparisons).

The research team concluded that medical cannabis may work as an adjunct therapy capable of reducing opioid dependence, relieving chronic pain, and improving quality of life in this patient population.

The Cost-Barrier Question

What distinguishes this study from much of the existing literature isn’t only the direction of the outcomes — it’s the deliberate removal of one of the biggest practical obstacles to medical cannabis access. The authors describe their work as “the first prospective observational study evaluating medical cannabis as an alternative to opioids in a setting where cost was removed as a major barrier.”

This framing matters clinically. Most studies capturing cannabis and opioid outcomes reflect real-world conditions where patients self-fund cannabis — often at significant expense, without any insurance reimbursement pathway. By eliminating cost as a variable, the Penn researchers tested something closer to a best-case access scenario: what happens when patients who want to try cannabis actually can?

In this cohort, the answer was measurable opioid reduction. The authors described medical cannabis as potentially serving as “a harm-reduction tool for some patients seeking to reduce reliance on higher-risk opioid medications” — a deliberate inversion of the long-standing “gateway drug” framing. For background on the receptor pharmacology underlying cannabis-as-pain-treatment research, our earlier piece on CB1 Therapies: A New Cannabis-Based Alternative to Opioids covers the mechanism.

What the Study Can and Can’t Tell Us

The methodology shapes what can actually be concluded. The Penn trial enrolled 29 patients at a single clinical site, had no control group, and allowed participants to self-titrate their cannabis products — meaning dose, frequency, and product type varied across participants. These limitations are ones the authors flag directly.

Without a control group, it’s not possible to rule out competing explanations for the opioid reduction: natural regression in a self-selected patient group, increased clinical engagement during follow-up, or uncontrolled confounders. Without standardized dosing, the study can’t isolate which cannabis formulations or THC/CBD ratios drove the observed effects. The authors call for larger, controlled trials before the findings can be applied at scale.

That caveat doesn’t render the signal meaningless — it contextualizes it. The Penn study joins a growing body of observational data pointing in the same direction.

A more rigorous dataset came from New York State. A prospective cohort study published in JAMA Internal Medicine in February 2026 — the Medical Marijuana and Opioids (MeMO) Study — tracked 204 adults over 18 months within New York’s pharmacist-supervised cannabis program. It found that participants dispensed a 30-day supply of medical cannabis in any given month used 3.53 fewer MMEs per day compared to months when no cannabis was dispensed. Mean daily opioid use fell 22% over 18 months. The MeMO Study used marginal structural models to account for time-varying confounders including unregulated cannabis use — a methodological step the Penn study wasn’t designed to replicate.

Neither study is a randomized controlled trial, the design needed to establish causation rather than correlation. But together they build the case that access to medical cannabis is associated with clinically meaningful reductions in prescription opioid use among chronic pain patients. The specific question the Penn study raises — whether removing the cost barrier changes who benefits and by how much — remains one for larger, prospective trials to address directly.